Abstract
This report concerns our preliminary clinical experience in 44 cases of acute myeloblastic leukemia with 22 050 RP (Fig. 1), the benzoyl-hydrazone chlorhydrate of daunorubicin (DNR). Among the semi-synthetic derivatives of DNR, 22 050 RP in L 1210 leukemia has a better therapeutic index than DNR (10 to 15 for 22 050 RP, 5 to 10 for DNR). Moreover, it is 50% less toxic than DNR and 75% less toxic than adriamycin [3].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bonadonna, G., Monfardini, S., de Lena, M., Fossati-Bellani, F.: Clinical evaluation of Adriamycin, a new antitumor antibiotic. Brit. med. J. 3, 5669, 503–506 (1969).
Ellison, R. R., Holland, J. F., Weil, M., Jacquillat, CL., Boiron, M., Bernard, J., Sawitsky, A., Rosner, F., Gussoff, B., Silver, R. T., Karanas, A., Cuttner, J., Spurr, C. L., Hayes, D. M., Blom, J. L., Leone, L. A., Haurani, F., Kyle, R., Hutchison, J. L., Forcier, L. J., Moon, J. H.: Arabinosyl Cytosine: A useful agent in the treatment of acute leukemia in adults. Blood 4, 507–523 (1968).
Maral, R., Julou, L., Ganter, P., Populaire, P., Pasquet, J., Pascal, S., Detaille, J. Y., Delsques, M., Myon, J., Mondot, S.: Laboratoire de Recherches de la Société des Usines Chimiques Rhône Poulenc Vitry-sur-Seine (94). Etude de l’activité antitumorale et de la toxicité du 22 050 RP (Communication personnelle).
Skeel, R. T., Bertino, J. R., Creasey, W. A.: Clinical and pharmacologic studies with Daunorubicin in acute leukemia (Abstract). Clin. Res. 18, 2476 (1970).
Weil, M., Glidewell, O., Jacquillat, Cl., Boiron, M., Bernard, J., Holland, J. F.: Studies of various doses and schedules of administration of Daunorubicin in acute granulocytic leukemia (analysis of A.L.G.B. protocols 6706 and 6706 A.) (in press).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1973 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Jacquillat, C., Weil, M., Gemon, MF., Izrael, V., Boiron, M., Bernard, J. (1973). A New Agent Active in the Treatment of Acute Myeloblastic Leukemia 22 050 RP. In: Mathé, G., Pouillart, P., Schwarzenberg, L. (eds) Nomenclature, Methodology and Results of Clinical Trials in Acute Leukemias. Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer, vol 43. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80776-3_26
Download citation
DOI: https://doi.org/10.1007/978-3-642-80776-3_26
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-80778-7
Online ISBN: 978-3-642-80776-3
eBook Packages: Springer Book Archive